American Journal of Kidney Diseases
Volume 54, Issue 2 , Pages 205-226 , August 2009

Proteinuria as a Surrogate Outcome in CKD: Report of a Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration

  • Andrew S. Levey, MD

      Affiliations

    • Tufts Medical Center, Boston, MA
    • ,
  • Daniel Cattran, MD

      Affiliations

    • Toronto General Hospital, Toronto, ON, Canada
    • ,
  • Aaron Friedman, MD

      Affiliations

    • University of Minnesota, Minneapolis, MN
    • ,
  • W. Greg Miller, PhD

      Affiliations

    • Virginia Commonwealth University, Richmond, VA
    • ,
  • John Sedor, MD

      Affiliations

    • Case Western Reserve University, Cleveland, OH
    • ,
  • Katherine Tuttle, MD

      Affiliations

    • University of Washington, Seattle and Spokane, WA
    • ,
  • Bertram Kasiske, MD

      Affiliations

    • Hennepin County Medical Center, Minneapolis, MN
    • ,
  • Thomas Hostetter, MD

      Affiliations

    • Albert Einstein College of Medicine, Bronx, NY

Received 7 February 2009 ,Accepted 13 April 2009.

References 

  1. Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: Approaches and initiatives—A position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007;72:247–259
  2. Levey A, Schoolwerth A, Rios Burrows N, Williams D, Stith K, McClellan W. Comprehensive public health strategies for preventing the development, progression, and complications of chronic kidney disease: Report of an expert panel convened by the Centers of Disease Control and Prevention. Am J Kidney Dis. 2009;55:522–535
  3. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–2047
  4. Himmelfarb J. Chronic kidney disease and the public health: Gaps in evidence from interventional trials. JAMA. 2007;297:2630–2633
  5. Strippoli GF, Craig JC, Schena FP. The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol. 2004;15:411–419
  6. National Kidney Foundation. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Am J Kidney Dis. 2004;43(suppl 1):S1–S290
  7. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49(suppl 2):S12–S154
  8. Stevens LA, Greene T, Levey AS. Surrogate end points for clinical trials of kidney disease progression. Clin J Am Soc Nephrol. 2006;1:874–884
  9. Eknoyan G, Hostetter T, Bakris GL, et al. Proteinuria and other markers of chronic kidney disease: A position statement of the National Kidney Foundation (NKF) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Am J Kidney Dis. 2003;42:617–622
  10. Proteinuria as a Surrogate Outcome in Chronic Kidney Disease: A workshop co-sponsored by the National Kidney Foundation and the U.S. Food and Drug Administration. http://www.kidney.org/professionals/physicians/proteinuria.cfmAccessed July 9, 2008
  11. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl 1):S1–S266
  12. Stevens LA, Lafayette LA, Perone RD, Levey AS. Laboratory evaluation of kidney disease. In:  Schrier RW editors. Diseases of the Kidney and Urinary Tract. Philadelphia, PA: Lippincott Williams & Wilkins; 2007;p. 299–366
  13. Warram JH, Gearin G, Laffel L, Krolewski AS. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol. 1996;7:930–937
  14. Miller GW, Burns DE, Hortin G, et al. Current issues in measurement and reporting of urinary albumin excretion. Clin Chem. 2009;55:24–38
  15. de Jong PE, Curhan GC. Screening, monitoring, and treatment of albuminuria: Public health perspectives. J Am Soc Nephrol. 2006;17:2120–2126
  16. Forman JP, Fisher ND, Schopick EL, Curhan GC. Higher levels of albuminuria within the normal range predict incident hypertension. J Am Soc Nephrol. 2008;19:1983–1988
  17. Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777–1782
  18. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154–2169
  19. Tuttle KR, Puhlman ME, Cooney SK, Short R. Urinary albumin and insulin as predictors of coronary artery disease: An angiographic study. Am J Kidney Dis. 1999;34:918–925
  20. Psaty BM, Lumley T. Surrogate end points and FDA approval: A tale of 2 lipid-altering drugs. JAMA. 2008;299:1474–1476
  21. Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs?. JAMA. 1999;282:790–795
  22. US Food and Drug Administration. Investigational New Drug Process. http://www.fda.gov/cder/about/smallbiz/faq.htm#IntroductionAccessed December 28, 2008
  23. FDA-CDER: Drug Review and Related Activities in the United States. FDA-CDER Forum for International Regulatory Authorities http://www.fda.gov/cder/audiences/iact/forum/200609_kremzner.pdfAccessed December 28, 2008
  24. Code of Federal Regulations-21CFR314.125: Refusal to approve an application. Food and Drug Administration, Department of Health and Human Resources http://edocket.access.gpo.gov/cfr_2002/aprqtr/21cfr314.125.htmAccessed June 22, 2009
  25. Warner-Lambert Co v Heckler, 1986 787 F.2d 147 (3d Cir, 1986)
  26. Code of Federal Regulations-21CFR314.510: Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity. Food and Drug Administration, Department of Health and Human Resources http://edocket.access.gpo.gov/cfr_2002/aprqtr/21cfr314.510.htmAccessed January 15, 2009
  27. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95
  28. Desai M, Stockbridge N, Temple R. Blood pressure as an example of a biomarker that functions as a surrogate. AAPS J. 2006;8:E146–E152
  29. Slomianka L. Tubules of the Nephron. University of Western Australia http://www.lab.anhb.uwa.edu.au/mb140/corepages/urinary/urinary.htmAccessed January 15, 2009
  30. Haraldsson B, Nystrom J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev. 2008;88:451–487
  31. Hewitt SM, Dear J, Star RA. Discovery of protein biomarkers for renal diseases. J Am Soc Nephrol. 2004;15:1677–1689
  32. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest. 2006;116:288–296
  33. Bohrer MP, Deen WM, Robertson CR, Brenner BM. Mechanism of angiotensin II-induced proteinuria in the rat. Am J Physiol. 1977;233:F13–F21
  34. Lapinski R, Perico N, Remuzzi A, Sangalli F, Benigni A, Remuzzi G. Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. J Am Soc Nephrol. 1996;7:653–660
  35. Fleming TR, DeMets DL. Surrogate end points in clinical trials: Are we being misled?. Ann Intern Med. 1996;125:605–613
  36. Frangakis CE, Rubin DB. Principal stratification in causal inference. Biometrics. 2002;58:21–29
  37. Joffe M, Greene T. Related causal framework for surrogate outcomes. Biometrics. 2009;65:530–538
  38. Burzykowski T, Chmielarczyk W. Predicted and observed thyroid cancer incidence in Poland after year 1986. Wiad Lek. 2004;57:306–310
  39. Burzykowski T, Molenberghs G, Buyse M. The validation of surrogate end points by using data from randomized clinical trials: A case-study in advanced colorectal cancer. J R Statist Soc A. 2004;167:103–124
  40. Molitch M, Rutledge B, Steffes M, Cleary P: Renal Insufficiency in the Absence of Albuminuria in Adults with Type 1 Diabetes in the Epidemiology of Diabetes Interventions and Complications (EPIC) Study. Poster presented at the 66th Annual Meeting of the American Diabetes Association, June 9-13, 2006, Washington, DC
  41. Nelson RG, Knowler WC, Pettitt DJ, Saad MF, Charles MA, Bennett PH. Assessment of risk of overt nephropathy in diabetic patients from albumin excretion in untimed urine specimens. Arch Intern Med. 1991;151:1761–1765
  42. Pavkov ME, Knowler WC, Hanson RL, Bennett PH, Nelson RG. Predictive power of sequential measures of albuminuria for progression to ESRD or death in Pima Indians with type 2 diabetes. Am J Kidney Dis. 2008;51:759–766
  43. Pavkov ME, Mason CC, Bennett PH, Curtis JM, Knowler WC, Nelson RG: Change in the distribution of albuminuria according to estimated glomerular filtration rate in Pima with type 2 diabetes. Diabetes Care (in press)
  44. UK Prospective Diabetes (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) (UK Prospective Diabetes Study (UKPDS) Group). Lancet. 1998;352:837–853
  45. UK Prospective Diabetes (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 (UK Prospective Diabetes Study Group). BMJ. 1998;317:703–713
  46. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63:225–232
  47. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes. 2006;55:1832–1839
  48. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 2003;348:2285–2293
  49. Perkins BA, Ficociello LH, Roshan B, et al. Decline in renal function to end stage renal disease begins soon after the onset of microalbuminuria (MA) in type 1 diabetes: Results of a 12 year follow-up. J Am Soc Nephrol. 2007;18:44A;(abstr)
  50. Perkins BA, Ficociello LH, Ostrander BE, et al. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol. 2007;18:1353–1361
  51. Perkins BA, Nelson RG, Krolewski AS. Cystatin C and the risk of death. N Engl J Med. 2005;353:842–844
  52. Mann JF, Gerstein HC, Yi QL, et al. Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: Results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. Am J Kidney Dis. 2003;42:936–942
  53. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–878
  54. Lambers Heerspink HJ, Fowler MJ, Volgi J, et al. Rationale for and study design of the sulodexide trials in type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy. Diabet Med. 2007;24:1290–1295
  55. Chen YE, Korbet SM, Katz RS, Schwartz MM, Lewis EJ. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol. 2008;3:46–53
  56. Grootscholten C, Ligtenberg G, Hagen EC, et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis (A randomized controlled trial). Kidney Int. 2006;70:732–742
  57. Moroni G, Quaglini S, Gallelli B, Banfi G, Messa P, Ponticelli C. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol Dial Transplant. 2007;22:2531–2539
  58. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46:2121–2131
  59. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: Lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum. 2004;50:3934–3940
  60. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353:2219–2228
  61. Chan TM, Tse KC, Tang CS, Mok MY, Li FK. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005;16:1076–1084
  62. Boumpas DT, Austin HA, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992;340:741–745
  63. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC. Idiopathic membranous nephropathy: Definition and relevance of a partial remission. Kidney Int. 2004;66:1199–1205
  64. Ponticelli C, Villa M, Banfi G, et al. Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis?. Am J Kidney Dis. 1999;34:618–625
  65. Jha V, Ganguli A, Saha TK, et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol. 2007;18:1899–1904
  66. Cattran DC, Rao P. Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis. 1998;32:72–79
  67. Rydel JJ, Korbet SM, Borok RZ, Schwartz MM. Focal segmental glomerular sclerosis in adults: Presentation, course, and response to treatment. Am J Kidney Dis. 1995;25:534–542
  68. Ponticelli C, Villa M, Banfi G, et al. Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis?. Am J Kidney Dis. 1999;34:618–625
  69. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC. Focal and segmental glomerulosclerosis: Definition and relevance of a partial remission. J Am Soc Nephrol. 2005;16:1061–1068
  70. Cattran DC, Appel GB, Hebert LA, et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: A randomized trial. Kidney Int. 2001;59:1484–1490
  71. Praga M, Barrio V, Juarez GF, Luno J. Tacrolimus monotherapy in membranous nephropathy: A randomized controlled trial. Kidney Int. 2007;71:924–930
  72. Alexopoulos E, Papagianni A, Tsamelashvili M, Leontsini M, Memmos D. Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome. Nephrol Dial Transplant. 2006;21:3127–3132
  73. Cattran DC, Appel GB, Hebert LA, et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis (North America Nephrotic Syndrome Study Group). Kidney Int. 1999;56:2220–2226
  74. GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy (The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)). Lancet. 1997;349:1857–1863
  75. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860
  76. Shahinfar S, Dickson TZ, Ahmed T, et al. Losartan in patients with type 2 diabetes and proteinuria: Observations from the RENAAL Study. Kidney Int Suppl. 2002;82:S64–S67
  77. de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int. 2004;65:2309–2320
  78. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354:359–364
  79. Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): Multicentre, randomised controlled trial. Lancet. 2005;365:939–946
  80. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease (A meta-analysis of patient-level data). Ann Intern Med. 2001;135:73–87
  81. Lea J, Greene T, Hebert L, et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: Results of the African American Study of Kidney Disease and Hypertension. Arch Intern Med. 2005;165:947–953
  82. Hunsicker LG, Adler S, Caggiula A, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int. 1997;51:1908–1919
  83. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease (The Modification of Diet in Renal Disease Study). Ann Intern Med. 1995;123:754–762
  84. Bartosik LP, Lajoie G, Sugar L, Cattran DC. Predicting progression in IgA nephropathy. Am J Kidney Dis. 2001;38:728–735
  85. Descamps-Latscha B, Witko-Sarsat V, et al. Early prediction of IgA nephropathy progression: Proteinuria and AOPP are strong prognostic markers. Kidney Int. 2004;66:1606–1612
  86. Praga M, Gutierrez E, Gonzalez E, Morales E, Hernandez E. Treatment of IgA nephropathy with ACE inhibitors: A randomized and controlled trial. J Am Soc Nephrol. 2003;14:1578–1583
  87. Kobayashi Y, Hiki Y, Kokubo T, Horii A, Tateno S. Steroid therapy during the early stage of progressive IgA nephropathy (A 10-year follow-up study). Nephron. 1996;72:237–242
  88. Pozzi C, Bolasco PG, Fogazzi GB, et al. Corticosteroids in IgA nephropathy: A randomised controlled trial. Lancet. 1999;353:883–887
  89. Yoshikawa N, Honda M, Iijima K, et al. Steroid treatment for severe childhood IgA nephropathy: A randomized, controlled trial. Clin J Am Soc Nephrol. 2006;1:511–517
  90. Najafian B, Kim Y, Crosson JT, Mauer M. Atubular glomeruli and glomerulotubular junction abnormalities in diabetic nephropathy. J Am Soc Nephrol. 2003;14:908–917
  91. Pagtalunan ME, Miller PL, Jumping-Eagle S, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest. 1997;99:342–348
  92. Toyoda M, Najafian B, Kim Y, Caramori ML, Mauer M. Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes. 2007;56:2155–2160
  93. Chan JC, Cheung CK, Cheung MY, Swaminathan R, Critchley JA, Cockram CS. Abnormal albuminuria as a predictor of mortality and renal impairment in Chinese patients with NIDDM. Diabetes Care. 1995;18:1013–1016
  94. Ibsen H, Olsen MH, Wachtell K, et al. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? (The LIFE Study). Diabetes Care. 2006;29:595–600
  95. Mathiesen ER, Ronn B, Storm B, Foght H, Deckert T. The natural course of microalbuminuria in insulin-dependent diabetes: A 10-year prospective study. Diabet Med. 1995;12:482–487
  96. Messent JW, Elliott TG, Hill RD, Jarrett RJ, Keen H, Viberti GC. Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: A twenty-three year follow-up study. Kidney Int. 1992;41:836–839
  97. Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke. 1996;27:2033–2039
  98. Nelson RG, Bennett PH, Beck GJ, et al. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus (Diabetic Renal Disease Study Group). N Engl J Med. 1996;335:1636–1642
  99. Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med. 2000;160:1093–1100
  100. Stoycheff N, Stevens LA, Schmid C, et al: Nephrotic syndrome in diabetic kidney disease: An evaluation and update of the definition [e-pub ahead of print]. Am J Kidney Dis doi:10.1053/j.ajkd.2009.04.016, accessed June 25, 2009
  101. Appel GB, Blum CB, Chien S, Kunis CL, Appel AS. The hyperlipidemia of the nephrotic syndrome (Relation to plasma albumin concentration, oncotic pressure, and viscosity). N Engl J Med. 1985;312:1544–1548
  102. Myers BD, Nelson RG, Tan M, et al. Progression of overt nephropathy in non-insulin-dependent diabetes. Kidney Int. 1995;47:1781–1789
  103. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med. 1982;307:652–659
  104. Zoja C, Benigni A, Remuzzi G. Cellular responses to protein overload: Key event in renal disease progression. Curr Opin Nephrol Hypertens. 2004;13:31–37
  105. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial [Erratum in: Lancet 361:1230, 2003]. Lancet. 2003;361:117–124
  106. Kunz R, Wolbers M, Glass T, Mann JF. The COOPERATE trial: A letter of concern. Lancet. 2008;371:1575–1576
  107. Appel LJ, Wright JT, Greene T, et al. Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med. 2008;168:832–839
  108. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869
  109. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–2997
  110. Rahman M, Pressel S, Davis BR, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165:936–946
  111. Rahman M, Pressel S, Davis BR, et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med. 2006;144:172–180
  112. Levey AS, Uhlig K. Which antihypertensive agents in chronic kidney disease?. Ann Intern Med. 2006;144:213–215
  113. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547–553
  114. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–1559
  115. Ruggenenti P, Perticucci E, Cravedi P, et al. Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol. 2008;19:1213–1224
  116. US Food and Drug Administration. FDA, European Medicines Agency to Consider Additional Test Results When Assessing New Drug Safety. http://www.fda.gov/bbs/topics/NEWS/2008/NEW01850.htmlAccessed January 31, 2009
  117. Clinical Data Interchange Standards Consortium (CDISC). Cardiovascular and Tuberculosis Data Standards. http://cdisc.org/standards/cardio/index.htmlAccessed January 31, 2009

 Originally published online as doi: 10.1053/j.ajkd.2009.04.029 on July 6, 2009.

 Because an author of this manuscript is an editor for AJKD, the peer-review and decision-making processes were handled entirely by an Associate Editor (Rulan Parekh, MD, MS, Johns Hopkins Medical Institutions) who served as Acting Editor-in-Chief. Details of the journal's procedures for potential editor conflicts are given in the Editorial Policies section of the AJKD website.

 Reprint requests to: Kerry Willis, PhD, National Kidney Foundation, 30 E 33rd St, New York, NY 10016. E-mail: kerryw@kidney.org

PII: S0272-6386(09)00763-X

doi: 10.1053/j.ajkd.2009.04.029

American Journal of Kidney Diseases
Volume 54, Issue 2 , Pages 205-226 , August 2009

Article Tools

* Image Usage & Resolution